The National Institute for Health and Care Excellence (NICE) has given a vital boost to thousands of women living with early breast cancer. Following its latest appraisal, NICE has recommended that Kisqali (ribociclib), a revolutionary new drug from Novartis, should be made available on the NHS for eligible patients at high risk of their cancer returning.
This decision is a major breakthrough in breast cancer care, as it offers a lifeline to those who are most at risk. Clinical trials have shown that Kisqali is incredibly effective in reducing the likelihood of disease recurrence in this patient group, and its availability will give clinicians an important new tool to tailor treatment plans to each individual's needs.
Breast cancer affects more than 55,000 people every year in the UK, with around 70% of cases being hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). While many patients respond well to initial treatments such as surgery, chemotherapy, and endocrine therapy, a significant proportion are at risk of recurrence – sometimes years after their diagnosis. This new recommendation aims to address this unmet need and give hope to those facing the highest risk.
The availability of Kisqali on the NHS will be a game-changer for thousands of women each year, potentially extending disease-free survival for those who need it most. NICE has carefully evaluated the clinical effectiveness and cost-effectiveness of the treatment, ensuring that its benefits outweigh any costs – in line with the NHS's commitment to providing access to innovative medicines.
According to the latest figures from Cancer Research UK, breast cancer is one of the most common cancers in the UK. In fact, around 1 in 8 women will develop the condition at some point in their lives. This new recommendation from NICE reflects its ongoing efforts to ensure that patients have access to the best possible treatments and care.